ALKS

33.53

0.47% -0.16

Handel nachbörslich: 33.53

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$33.69

Offen:

$34.41

24-Stunden-Volumen:

1.08M

Relative Volume:

0.69

Marktkapitalisierung:

$5.45B

Einnahmen:

$1.51B

Nettoeinkommen (Verlust:

$333.35M

KGV:

17.19

EPS:

1.95

Netto-Cashflow:

$315.22M

1W Leistung:

-1.15%

1M Leistung:

-1.50%

6M Leistung:

+21.79%

1J Leistung:

+23.05%

1-Tages-Spanne:

$33.50

$34.45

1-Wochen-Bereich:

$33.22

$35.41

52-Wochen-Spanne:

$22.90

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1179)

Branche

Drug Manufacturers - Specialty & Generic (1)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

1,800

Twitter

@alkermes

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Vergleichen Sie ALKS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	33.53	5.45B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	165.02	73.07B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.14	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.12	45.72B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.49	17.75B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.75	14.03B	612.78M	-86.37M	-62.91M	-0.87

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-03-04	Hochstufung	UBS	Sell → Neutral
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

08:14 AM

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - Marketscreener.com

08:14 AM

08:00 AM

What 5 Analyst Ratings Have To Say About Alkermes - Benzinga

08:00 AM

07:00 AM

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire

07:00 AM

Mar 26, 2025

Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com

Mar 15, 2025

Mar 14, 2025

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance

Mar 14, 2025

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025

Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com

Mar 14, 2025

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance

Mar 14, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St

Mar 14, 2025

Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025

RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq

Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025

Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa

Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025

Mar 11, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times

Mar 11, 2025

Mar 09, 2025

Alkermes Plc to Host Earnings Call - ACCESS Newswire

Mar 09, 2025

Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC - Defense World

Mar 09, 2025

Proficio Capital Partners LLC Buys New Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 09, 2025

Mar 08, 2025

(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 08, 2025

What is Zacks Research’s Estimate for Alkermes Q1 Earnings? - Defense World

Mar 08, 2025

Mar 07, 2025

Zacks Research Predicts Alkermes FY2027 Earnings - Defense World

Mar 07, 2025

UBS Group Upgrades Alkermes (NASDAQ:ALKS) to Neutral - MarketBeat

Mar 07, 2025

Mar 06, 2025

Y Intercept Hong Kong Ltd Invests $413,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Mar 06, 2025

Mar 05, 2025

UBS Upgrades Alkermes (ALKS) - Nasdaq

Mar 05, 2025

Bank of New York Mellon Corp Has $61.45 Million Stock Holdings in Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 05, 2025

Alkermes (NASDAQ:ALKS) Upgraded to Neutral at UBS Group - Defense World

Mar 05, 2025

Mar 04, 2025

UBS Upgrades Alkermes to Neutral From Sell, $38 Price Target -March 04, 2025 at 08:27 am EST - Marketscreener.com

Mar 04, 2025

Alkermes upgraded to Neutral from Sell at UBS - TipRanks

Mar 04, 2025

Mar 01, 2025